Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery CellsJohn Wharton, Martin R. Wilkins, Julian Strange et al.|American Journal of Respiratory and Critical Care Medicine|2005Cited by 367
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patientsEvangelos D. Michelakis, Martin R. Wilkins, Vikram Gurtu et al.|Science Translational Medicine|2017Cited by 311
Histone Deacetylation Inhibition in Pulmonary HypertensionLan Zhao, Martin R. Wilkins, Emanuele Cotroneo et al.|Circulation|2012Cited by 260
Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial HypertensionChristopher J. Rhodes, Martin R. Wilkins, Luke Howard et al.|Journal of the American College of Cardiology|2011Cited by 259
Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary HypertensionAbdelkrim Sebkhi, Martin R. Wilkins, Julian Strange et al.|Circulation|2003Cited by 256